0J2O Stock Overview A biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteHalozyme Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Halozyme Therapeutics Historical stock prices Current Share Price US$47.44 52 Week High US$65.40 52 Week Low US$33.22 Beta 1.24 1 Month Change -1.25% 3 Month Change -17.04% 1 Year Change 28.49% 3 Year Change 18.31% 5 Year Change n/a Change since IPO 150.48%
Recent News & Updates
Investor sentiment deteriorates as stock falls 20% Nov 21
New minor risk - Share price stability Nov 15 Halozyme Reportedly Interested in Acquiring Evotec for $2.1 Billion
Investor sentiment improves as stock rises 18% Nov 07
Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.62 in 3Q 2023) Nov 01
Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2024 Nov 01 See more updates
Investor sentiment deteriorates as stock falls 20% Nov 21
New minor risk - Share price stability Nov 15 Halozyme Reportedly Interested in Acquiring Evotec for $2.1 Billion
Investor sentiment improves as stock rises 18% Nov 07
Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.62 in 3Q 2023) Nov 01
Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2024 Nov 01
Halozyme Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 24
Investor sentiment deteriorates as stock falls 18% Oct 10 Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis Sep 14
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer Sep 13
Independent Director recently sold US$1.7m worth of stock Aug 15
Second quarter 2024 earnings released: EPS: US$0.73 (vs US$0.57 in 2Q 2023) Aug 07
Halozyme Therapeutics, Inc. Reiterates Financial Guidance for 2024 Aug 07
Halozyme Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 23
Halozyme Therapeutics, Inc. Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis Jun 25
Halozyme Therapeutics, Inc. Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy Jun 22
Independent Director recently sold US$1.0m worth of stock Jun 14
Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024 Jun 08
Investor sentiment improves as stock rises 19% Jun 07
First quarter 2024 earnings released: EPS: US$0.60 (vs US$0.29 in 1Q 2023) May 08
Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024 May 08
Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors Apr 27
Halozyme Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 24
Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024 Mar 16
Full year 2023 earnings released: EPS: US$2.13 (vs US$1.48 in FY 2022) Feb 21 Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024
Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024 Feb 09
Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis Jan 19
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023 Jan 18
Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy Jan 17
Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types Jan 16
Third quarter 2023 earnings released: EPS: US$0.62 (vs US$0.45 in 3Q 2022) Nov 07
Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 31
Halozyme Therapeutics, Inc. Reports Positive Topline Results from the Phase 3 Checkmate-67T Trial Evaluating Subcutaneous (SC) Formulation of Opdivo (Nivolumab) with Enhanze Oct 20
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery Oct 17
Halozyme Therapeutics, Inc Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain Aug 30
Independent Director recently sold US$875k worth of stock Aug 17
Second quarter 2023 earnings released: EPS: US$0.57 (vs US$0.16 in 2Q 2022) Aug 09
Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023 Aug 09
Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy Jul 17
Positive Results Announces from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis Jul 13 Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo With ENHANZE for Subcutaneous Use in Generalized Myasthenia Gravis Jun 21
Insufficient new directors Jun 07
First quarter 2023 earnings released: EPS: US$0.29 (vs US$0.44 in 1Q 2022) May 10
Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2023 May 10
Insufficient new directors Mar 27
Investor sentiment deteriorates as stock falls 19% Mar 17
Independent Director recently sold US$962k worth of stock Mar 06
Full year 2022 earnings released: EPS: US$1.48 (vs US$2.86 in FY 2021) Feb 22
Halozyme Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023 Feb 08
Halozyme Therapeutics Appoints Barbara Duncan to Its Board of Directors Feb 07
Halozyme Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2023 Jan 11
Independent Director recently sold US$1.7m worth of stock Dec 09
CFO & Director recently sold US$269k worth of stock Nov 17
Third quarter 2022 earnings released: EPS: US$0.45 (vs US$1.53 in 3Q 2021) Nov 10
Halozyme Therapeutics, Inc. Reiterates Financial Guidance for the Year 2022 Nov 09
Halozyme Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Second quarter 2022 earnings released: EPS: US$0.16 (vs US$0.64 in 2Q 2021) Aug 10
Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2022 Aug 10
Halozyme Therapeutics, Inc. Announces Positive Results from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq with ENHANZE in Advanced Non-Small Cell Lung Cancer Aug 02
Halozyme Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Investor sentiment improved over the past week Jul 08
Halozyme Therapeutics, Inc. Announces Commercial Launch of TLANDO, an Oral Treatment for Testosterone Replacement Therapy Jun 09
Investor sentiment improved over the past week May 28
Halozyme Therapeutics, Inc. (NasdaqGS:HALO) completed the acquisition of Antares Pharma, Inc. (NasdaqCM:ATRS). May 25
Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022 May 12
First quarter 2022 earnings released: EPS: US$0.44 (vs US$0.20 in 1Q 2021) May 11
Halozyme Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022 May 04
Insufficient new directors Apr 27
Halozyme Therapeutics, Inc. (NasdaqGS:HALO) entered into a definitive agreement to acquire Antares Pharma, Inc. (NasdaqCM:ATRS) for $970 million. Apr 15 Halozyme Therapeutics, Inc. (NasdaqGS:HALO) entered into a definitive agreement to acquire Antares Pharma, Inc. (NasdaqCM:ATRS) for $970 million. Apr 14
Insufficient new directors Mar 07
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022 Feb 24
Halozyme Therapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 10
Halozyme Therapeutics, Inc. Announces Executive Changes Feb 04
Halozyme Therapeutics, Inc. Announces Change of Chief Financial Officer Feb 03
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2022 Jan 12
Investor sentiment improved over the past week Dec 23
Halozyme Therapeutics, Inc. (NasdaqGS:HALO) announces an Equity Buyback for $750 million worth of its shares. Dec 10
Independent Chairperson of the Board recently sold US$1.3m worth of stock Nov 07
Third quarter 2021 earnings released: EPS US$1.53 (vs US$0.27 in 3Q 2020) Nov 04
Insufficient new directors Nov 01
Insufficient new directors Oct 02
Independent Director recently sold US$1.4m worth of stock Aug 27
Second quarter 2021 earnings released: EPS US$0.64 (vs US$0.19 in 2Q 2020) Aug 10
Halozyme Therapeutics, Inc. Announces Janssen Receives European Marketing Authorizations for Darzalex® (Daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-Chain Amyloidosis and Pre-Treated Multiple Myeloma Jun 23
First quarter 2021 earnings released: EPS US$0.20 (vs US$0.044 loss in 1Q 2020) May 12
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year of 2021 May 11 Shareholder Returns 0J2O GB Biotechs GB Market 7D -0.4% -1.9% -0.6% 1Y 28.5% -25.0% 2.7%
See full shareholder returns
Return vs Market: 0J2O exceeded the UK Market which returned 2.7% over the past year.
Price Volatility Is 0J2O's price volatile compared to industry and market? 0J2O volatility 0J2O Average Weekly Movement 8.8% Biotechs Industry Average Movement 7.0% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0J2O's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0J2O's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.
Show more Halozyme Therapeutics, Inc. Fundamentals Summary How do Halozyme Therapeutics's earnings and revenue compare to its market cap? 0J2O fundamental statistics Market cap US$6.05b Earnings (TTM ) US$392.47m Revenue (TTM ) US$947.36m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0J2O income statement (TTM ) Revenue US$947.36m Cost of Revenue US$249.60m Gross Profit US$697.75m Other Expenses US$305.29m Earnings US$392.47m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 3.08 Gross Margin 73.65% Net Profit Margin 41.43% Debt/Equity Ratio 332.3%
How did 0J2O perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 14:52 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Halozyme Therapeutics, Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research James Birchenough Barclays Robert Wasserman Benchmark Company
Show 31 more analysts